(Q34580994)

3 August 2017

1 reference

title

Differentiating members of the thiazolidinedione class: a focus on safety (English)

1 reference

3 August 2017

Harold E Lebovitz

1

1 reference

3 August 2017

publication date

1 March 2002

1 reference

Diabetes - Metabolism: Research and Reviews

3 August 2017

published in

1 reference

3 August 2017

volume

18 Suppl 2

1 reference

3 August 2017

page(s)

S23-9

1 reference

3 August 2017

1 reference

7 January 2021

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

7 January 2021

Trp64Arg mutation of beta3-adrenoceptor gene deteriorates lipolysis induced by beta3-adrenoceptor agonist in human omental adipocytes.

1 reference

7 January 2021

Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.

1 reference

7 January 2021

Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.

1 reference

7 January 2021

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

1 reference

7 January 2021

Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers

1 reference

7 January 2021

Hepatic dysfunction associated with troglitazone

1 reference

7 January 2021

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

1 reference

7 January 2021

Fatal hepatotoxicity associated with troglitazone

1 reference

7 January 2021

Troglitazone-induced hepatic failure leading to liver transplantation. A case report

1 reference

7 January 2021

Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone

1 reference

7 January 2021

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone

1 reference

7 January 2021

Clinical pharmacokinetics of troglitazone

1 reference

7 January 2021

Troglitazone has no effect on red cell mass or other erythropoietic parameters

1 reference

7 January 2021

Effect of troglitazone on body fat distribution in type 2 diabetic patients

1 reference

7 January 2021

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes

1 reference

7 January 2021

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

1 reference

7 January 2021

Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.

1 reference

7 January 2021

The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat.

1 reference

7 January 2021

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.252

1 reference

3 August 2017

1 reference